Ertapenem for Injection 1000mg | ECZAS - Glenmark

Advanced Broad-Spectrum Carbapenem Antibiotic

When managing severe, complicated, or hospital-acquired bacterial infections, healthcare providers require a highly potent and reliable intervention. The Ertapenem for Injection 1000mg (commercially recognized as ECZAS) provides a powerful, broad-spectrum carbapenem antibiotic therapy designed for critical care. Manufactured by Glenmark, a globally respected leader in pharmaceutical research and manufacturing, this single-use lyophilized vial ensures the steady clinical performance necessary for acute care and intensive recovery protocols.

Why Choose ECZAS for Critical Infection Management?

Tackling resistant bacterial strains requires an aggressive, targeted approach. Instead of relying on standard antibiotics that bacteria may easily bypass, clinical specialists benefit from ECZAS’s highly robust formulation. Ertapenem works by penetrating the bacterial cell wall and binding to penicillin-binding proteins (PBPs), effectively halting bacterial growth and providing hospitals with a reliable defense against complex intra-abdominal, pelvic, and complicated skin infections. Glenmark ensures the stringent quality control demanded in critical care environments.

Key Product Specifications & Clinical Benefits

Potent Active Ingredient: Each vial contains premium-grade Ertapenem Sodium equivalent to 1000mg (1g) of Anhydrous Ertapenem, delivering a highly concentrated antibiotic dose.

Versatile Delivery: Formulated safely for both Intravenous (I.V.) and Intramuscular (I.M.) use, giving practitioners flexible delivery methods based on patient protocols and acute care needs.

Lyophilized Stability: Supplied as a lyophilized (freeze-dried) powder, ensuring the absolute stability and potency of the active ingredient until the exact moment of clinical reconstitution.

Hygienic Single-Use Vial: Packaged as a sterile, single-use vial, strictly minimizing the risk of cross-contamination during critical care preparation and administration.

Essential Storage & Usage Guidelines

Maintaining the integrity of this critical care medication is vital for its clinical efficacy. Store the lyophilized powder below 25°C. Protect strictly from light and moisture.

I.V. Use: The reconstituted solution should be used within 6 hours of preparation if stored below 25°C, or within 24 hours if stored under refrigeration (2°C to 8°C). Solution should not be frozen.

I.M. Use: The reconstituted I.M. solution should be used within 1 hour after preparation.

Important Notice: ECZAS is a Schedule H1 Prescription Drug. It must be prescribed, prepared, and administered strictly by a Registered Medical Practitioner in a clinical or hospital setting. Keep all medicines safely out of the reach of children.